GLPG1205 for idiopathic pulmonary fibrosis: a phase 2 randomised placebo-controlled trial

BACKGROUND: GLPG1205 is a selective functional antagonist of G-protein-coupled receptor 84, which plays an important role in fibrotic processes. This study assessed the efficacy, safety and tolerability of GLPG1205 for treatment of idiopathic pulmonary fibrosis (IPF). METHODS: PINTA (ClinicalTrials....

Descripción completa

Detalles Bibliográficos
Autores principales: Strambu, Irina R., Seemayer, Christian A., Fagard, Liesbeth M-C.A., Ford, Paul A., Van der Aa, Tom A.K., de Haas-Amatsaleh, Angela A., Modgill, Vikas, Santermans, Eva, Sondag, Eric N., Helmer, Eric G., Maher, Toby M., Costabel, Ulrich, Cottin, Vincent
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2023
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9978158/
https://www.ncbi.nlm.nih.gov/pubmed/36328358
http://dx.doi.org/10.1183/13993003.01794-2022

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9978158/
https://www.ncbi.nlm.nih.gov/pubmed/36328358
http://dx.doi.org/10.1183/13993003.01794-2022

Ejemplares similares